Chronological vs Biological Age in Interventional Cardiology

КАРДИОЛОГИЯ УЗБЕКИСТАНА, Journal Year: 2024, Volume and Issue: 17(8), P. 961 - 978

Published: April 1, 2024

Language: Английский

---

Aging in Heart Failure

JACC Heart Failure, Journal Year: 2024, Volume and Issue: 12(5), P. 795 - 809

Published: April 8, 2024

Language: Английский

---

Wild-type transthyretin cardiac amyloidosis: the need for a comprehensive geriatric assessment beyond age

European Heart Journal, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 26, 2025

Graphical AbstractWild type transthyretin cardiac amyloidosis (wtATTR-CM) is an age-related condition which results from the deposition of insoluble amyloid fibrils, formed by misfolding transthyretin, a protein produced liver. It progressive disease if left untreated. The improvement in non-invasive diagnostic pathways, coupled with raised awareness and recognition wtATTR-CM as treatable condition, has been associated exponential increase diagnosis especially patients over 80-year-old - underrepresented category clinical trials. Recent evidence suggests that while some octogenarians may gain benefit disease-specific therapy, others do not respond. For this reason, key future challenge will be to validate objective tools identify who are unlikely modifying treatment at same time discriminate simply on chronological age, overall aim those most intervention.Open new tabDownload slide

Language: Английский

---

Clinical Phenotype and Prognostic Significance of Frailty in Transthyretin Cardiac Amyloidosis

JACC CardioOncology, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

The prevalence and clinical impact of frailty in transthyretin cardiac amyloidosis (ATTR-CA) remains poorly characterized. This study aimed to evaluate the prevalence, determinants, prognostic significance a large cohort patients with ATTR-CA. Frailty was assessed 880 ATTR-CA (median age 80 years [Q1-Q3: 75-84 years], 719 [81.7%] male) using Clinical Scale (CFS). analyzed as continuous variable categorized CFS 1 3, 4 or 5, 6 7, 8 9. observed 502 (57.1%) (CFS 5: 364 [41.4%]; 7: 129 [14.7%]; 9: 9 [1.0%]). Independent predictors worsening included older age, female sex, non-p.(V142I) hereditary variants, National Amyloidosis Centre stage 3 disease. Mortality rates increased incrementally severity (deaths per 100 person-years: 2.9 vs 11.0 21.1 40.9; log-rank P < 0.001). independently associated higher mortality risk across all groups, genotypes, disease stages. is common linked risk. Incorporating assessment alongside traditional markers enhances prognostication genotypes severities, particularly for short-term estimation.

Language: Английский

---

Longitudinal analysis of physical function in older adults: The effects of physical inactivity and exercise training

Aging Cell, Journal Year: 2023, Volume and Issue: 23(1)

Published: Sept. 8, 2023

Abstract Lack of exercise contributes to systemic inflammation and is a major cause chronic disease. The long‐term impact initiating sustaining in late life, as opposed sedentary lifestyle, on whole‐body health measures such physical performance not well known. This an exploratory study compare changes among older adults life versus inactive adults. Data from two observational cohorts were included this analysis, representing activity groups. Active group cohort comprises ( n = 318; age 72.5 ± 7.2 years) enrolled supervised program, “Gerofit.” 146; 74.5 5.5 the Italian “Act Ageing” (AOA) who self‐reported being inactive. Participants both groups completed battery at baseline 1‐year including: 6‐min walk test, 30‐s chair stand, timed up‐and‐go. Two‐sample t ‐tests measured differences between Gerofit AOA across all measures. Significant between‐group effects seen for p s 0.001). declined 1 year (range −18% −24% change). experienced significant gains function +10% +31% Older initiated routine, sustained protected age‐related declines performance, while those remained suffered cumulative deficits strength, aerobic endurance, mobility. Interventions reduce behaviors increase are important promote multi‐system, health.

Language: Английский

---

Preclinical Studies on the Effects of Frailty in the Aging Heart

Canadian Journal of Cardiology, Journal Year: 2024, Volume and Issue: 40(8), P. 1379 - 1393

Published: March 7, 2024

Age is a major risk factor for the development of cardiovascular diseases in men and women. However, not all people age at same rate those who are aging rapidly considered frail, when compared to their fit counterparts. Frailty an important clinical challenge because frail more likely develop die from illnesses, including diseases, than age. This increase susceptibility older individuals may occur as cellular molecular mechanisms involved process facilitate structural functional damage heart. Consistent with this, recent studies murine frailty models have provided strong evidence that maladaptive cardiac remodeling mice most pronounced high level frailty. For example, there ventricular hypertrophy contractile dysfunction increases mice. Additionally, fibrosis slowing conduction sinoatrial node atria proportional These modifications could predispose adults like heart failure atrial fibrillation. preclinical work also raises possibility emerging interventions designed "treat frailty" treat or prevent diseases. findings help explain why these disorders they

Language: Английский

---

Frailty as an upstream target for intervention: A unifying approach to intervening in the trajectories of health, function, and disease in late life

Journal of the American Geriatrics Society, Journal Year: 2024, Volume and Issue: 72(6), P. 1650 - 1653

Published: March 18, 2024

Abstract This editorial comments on the article by Deiner et al . in this issue.

Language: Английский

---

Geroscience in heart failure: the search for therapeutic targets in the shared pathobiology of human aging and heart failure

The Journal of Cardiovascular Aging, Journal Year: 2025, Volume and Issue: 5(1)

Published: Jan. 15, 2025

Age is a major risk factor for heart failure, but one that has been historically viewed as non-modifiable. Emerging evidence suggests the biology of aging malleable, and can potentially be intervened upon to treat age-associated chronic diseases, such failure. While represents new frontier therapeutic target discovery in challenges translating Geroscience research clinic are multifold. In this review, we propose strategy prioritizes initial human biology. We review rationale starting with omics, which generated important insights into shared (patho)biology then discuss how knowledge leveraged identify mechanisms most relevant Lastly, provide examples human-first approach, when paired rigorous functional assessments preclinical models, leading early-stage clinical development gerotherapeutic approaches

Language: Английский

---

An Expert Opinion on the Management of Frailty in Heart Failure from the Australian Cardiovascular Alliance National Taskforce

Heart Lung and Circulation, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

---

Risk of senescence, polypharmacy, and their outcomes in elderly cardiovascular disease patients

Advances in pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---